01 September 2017 |
AIM: RENE |
Block Listing Review and Total Voting Rights
ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements:
|
Name: |
ReNeuron Group plc |
|
Name of Scheme: |
ReNeuron Share Option Schemes |
|
Period of Return: |
From 1 March 2017 to 31 August 2017 |
|
Balance of unallotted securities under scheme(s) from previous return: |
90,282,511 Ordinary Shares (of 1p each)
|
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last Review (if any increase has been applied for): |
N/A |
|
Less: Number of securities issued/allotted under scheme(s) during period |
N/A |
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
90,282,511 Ordinary Shares |
|
Number and class of securities originally admitted and the date of admission: |
2,000,000 Ordinary Shares on 13 May 2010 |
|
|
|
|
|
|
Total Voting Rights
The Company has 3,164,618,541 ordinary shares in issue, all with voting rights. The Company holds no ordinary shares in treasury. The figure of 3,164,618,541 Ordinary Shares may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure and Transparency Rules.
ENDS
ENQUIRIES:
|
ReNeuron |
+44 (0) 20 3819 8400 |
|
Olav Hellebø , Chief Executive Officer |
|
|
Michael Hunt, Chief Financial Officer |
|
|
Buchanan |
+44 (0) 20 7466 5000 |
|
Mark Court, Sophie Cowles, Stephanie Watson |
|
|
|
|
|
Stifel Nicolaus Europe Limited |
+44 (0) 20 7710 7600 |
|
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker) |
|
|
N+1 Singer Advisory LLP |
+44 (0) 20 7496 3000 |
|
Mark Taylor (Joint Broker) |
|
About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for motor disability as a result of stroke, for critical limb ischaemia and for the blindness-causing disease, retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for drugs that would otherwise lack adequate capacity to penetrate to their site of action.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.
